Zolgensma-Evrysdi Combo Likely Beneficial for SMA Type 1

Zolgensma-Evrysdi Combo Likely Beneficial for SMA Type 1

301733

Zolgensma-Evrysdi Combo Likely Beneficial for SMA Type 1

Daily treatment with Evrysdi (risdiplam) following the one-time gene therapy Zolgensma (onasemnogene abeparvovec-xioi) is generally well-tolerated and leads to motor improvements in children with spinal muscular atrophy (SMA) type 1, according to a case series study. While children were followed for a short time after Evrysdi was initiated and objective motor measures were not systematically used, these preliminary findings suggest that combining Zolgensma with Evrysdi may be a safe and beneficial approach for SMA type…

You must be logged in to read/download the full post.